A phase ii study of docetaxel and cisplatin in patients with recurrent or unresectable squamous cell carcinoma of the head and neck

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 8, 2009, Pages 1281-1285

  Hanai, Nobuhiro ^a   Terada, Akihiro ^a   Ozawa, Taijiro ^a   Hirakawa, Hitoshi ^a   Yokoi, Hisashi ^b   Hasegawa, Yasuhisa ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b KOMAKI CITY HOSPITAL   (Japan)

Author keywords

Cisplatin; Docetaxel; Squamous cell carcinoma of the head and neck

Indexed keywords

CISPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG RESPONSE; EMPHYSEMA; FEBRILE NEUTROPENIA; HEAD AND NECK CARCINOMA; HUMAN; INOPERABLE CANCER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PNEUMONIA; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VOMITING;

EID: 79959856497     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Schoffski P, Catimel G, Planting AS, et al: Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 10(1): 119-122, 1999. (Pubitemid 29090602)
2. Specht L, Larsen SK and Hanse HS: Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 11(7): 845-849, 2000.
3. Gedlicka C, Formanek M, Selzer E, et al: Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 63(2): 145-150, 2002.
4. Glisson BS, Murphy BA, Frenette G, et al: Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20(6): 1593-1599, 2002. (Pubitemid 34260540)
5. Caponigro F, Massa E, Manzione L, et al: Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 12(2): 199-202, 2001. (Pubitemid 32223868)
6. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5(6): 533-537, 1994.
7. Gibson MK, Li Y, Murphy B, et al: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23(15): 3562-3567, 2005.
8. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17): 1705-1715, 2007. (Pubitemid 350005152)
9. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17): 1695-1704, 2007. (Pubitemid 350005151)
10. Tsukuda M, Mikami Y, Tanigaki Y, et al: Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 9(3): 161-166, 2004. (Pubitemid 38899748)